Frankfurt
17.03.25 | 08:52
3,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.04. | OPTHEA LIMITED: Long Term Suspended Entities | 1 | ASX | ||
| 01.03. | OPTHEA LIMITED: Appendix 4D and Half Year Report for period 31 Dec 2025 | 1 | ASX | ||
| 29.01. | OPTHEA LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | 1 | ASX | ||
| 22.01. | OPTHEA LIMITED: Long Term Suspended Entities | 6 | ASX | ||
| 15.01. | OPTHEA LIMITED: Notification of cessation of securities - OPT | 2 | ASX | ||
| 22.12.25 | OPTHEA LIMITED: Change of Director's Interest Notice - KC & LG | - | ASX | ||
| 19.12.25 | OPTHEA LIMITED: Notification regarding unquoted securities - OPT | 1 | ASX | ||
| OPTHEA LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 17.12.25 | Health Check: No longer sheepish, Opthea flags fresh start | 3 | Stockhead | ||
| 17.12.25 | OPTHEA LIMITED: Investor Update Presentation | 2 | ASX | ||
| 11.12.25 | OPTHEA LIMITED: Notice of Market Update | 16 | ASX | ||
| 07.12.25 | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 20.11.25 | OPTHEA LIMITED: Voluntary delisting from Nasdaq takes effect | 1 | ASX | ||
| 20.11.25 | Opthea Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.11.25 | Opthea Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.11.25 | OPTHEA LIMITED: Results of AGM | 1 | ASX | ||
| 10.11.25 | Opthea Ltd - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | - | SEC Filings | ||
| 30.10.25 | OPTHEA LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 30.10.25 | Opthea Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.10.25 | OPTHEA LIMITED: Opthea announces intention to delist from Nasdaq | - | ASX |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 21,860 | +4,00 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,480 | -0,67 % | Cosciens Biopharma Inc: Cosciens Biopharma to exit U.S. reporting | ||
| HALOZYME THERAPEUTICS | 55,60 | -0,32 % | HALOZYME THERAPEUTICS, INC. - 8-K, Current Report | ||
| ABCELLERA BIOLOGICS | 3,545 | 0,00 % | Truist reiterates Buy on AbCellera stock, eyes 2H26 data readout | ||
| GLOW LIFETECH | 0,027 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Reports Fourth Quarter and Full Year 2025 Financial Results; 146% YoY Revenue Growth and Second Consecutive Quarter of Positive Cash Flow | Toronto, Ontario--(Newsfile Corp. - April 8, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the fourth... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 245,00 | 0,00 % | BIO-RAD LABORATORIES, INC. - 8-K, Current Report | ||
| AVID BIOSERVICES | - | - | Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California | COSTA MESA, Calif., Feb. 24, 2026 /PRNewswire/ -- Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state... ► Artikel lesen | |
| BIOLINERX | 1,720 | +3,61 % | BioLineRx Ltd.: BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers
GLIX1 has demonstrated potent... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 5,530 | -1,43 % | Minerva Neurosciences, Inc: Minerva Announces Leadership Transition | Jim O'Connor joins as Chief Business Officer and General CounselBURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,680 | +6,36 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 | MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets
MUC16 is highly and stably expressed in the most... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| OVID THERAPEUTICS | 2,300 | +2,68 % | H.C. Wainwright bestätigt Kaufempfehlung für Ovid Therapeutics | ||
| COCRYSTAL | 1,240 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus | Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,077 | 0,00 % | Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics | Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; "Applied"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 6,400 | +6,31 % | Precision BioSciences, Inc.: Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 | Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B
Precision... ► Artikel lesen |
Das Unternehmen OPTHEA LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OPTHEA LIMITED ADR finden Sie auf Wallstreet Online.